Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.